Is Novo Nordisk’s $NVO Growth Making It a Better Buy Than UnitedHealth $UNH?

The healthcare sector often presents intriguing opportunities for investors, particularly when comparing giants like Novo Nordisk (NVO) and UnitedHealth Group (UNH). A striking observation at the outset is that Novo Nordisk, despite its robust growth in the pharmaceutical space, particularly in obesity and diabetes treatments, appears to trade at a relatively modest valuation compared to its fundamentals. This analysis delves into the key financial metrics and growth trajectories of both companies, offering a balanced perspective on their investment potential as of mid-2025.

Financial Metrics: A Snapshot of Value

Novo Nordisk, a Danish pharmaceutical leader, has seen exceptional growth driven by its blockbuster drugs like Ozempic and Wegovy. For Q2 2025 (April to June), the company reported net sales of approximately DKK 68.1 billion, marking a year-on-year increase of 25%, according to the latest investor updates on their official site. This growth is underpinned by a 65% surge in obesity drug sales, a segment expected to expand significantly by the end of the decade. Notably, the price-to-earnings (P/E) ratio for Novo Nordisk stands at around 18.2x as of July 2025, suggesting a valuation that may not fully reflect its growth momentum when benchmarked against industry averages for high-growth pharmaceuticals, which often hover above 25x.

In contrast, UnitedHealth Group, a diversified healthcare conglomerate, operates across insurance and provider services. For the same period, Q2 2025, UnitedHealth reported revenues of approximately $98.9 billion, a more modest year-on-year growth of 6.5%, as per their latest earnings release. Its P/E ratio, however, sits at a higher 22.4x, reflecting a premium valuation despite slower top-line expansion. This discrepancy raises questions about whether the market is overpricing UnitedHealth’s stability relative to Novo Nordisk’s growth potential.

The table below summarises key metrics for both companies as of Q2 2025:

Growth Drivers and Market Positioning

Novo Nordisk’s dominance in the GLP-1 receptor agonist market for diabetes and obesity treatments positions it as a frontrunner in a niche with limited direct competition, at least for now. Forecasts suggest the obesity drug market alone could reach $100 billion by 2030, and Novo Nordisk is well-placed to capture a significant share with pipeline innovations. This growth narrative contrasts with UnitedHealth Group’s broader but less explosive trajectory. UnitedHealth benefits from a diversified model, with its Optum division driving efficiencies in healthcare delivery, yet it faces headwinds from regulatory scrutiny and margin pressures in its insurance segment.

Interestingly, while scanning sentiment on social platforms like X, a user named MMatters22596 has echoed a broader discussion around Novo Nordisk’s valuation appearing attractive relative to peers. This aligns with the data: Novo Nordisk’s forward-looking free cash flow projections for full-year 2025, estimated between DKK 56 billion and DKK 67 billion, further underscore its capacity to reinvest in growth while maintaining shareholder returns.

Valuation: Opportunity or Trap?

Comparing the two, Novo Nordisk’s lower P/E ratio and higher growth rate suggest it might be undervalued relative to UnitedHealth Group. However, valuation is not a standalone metric. UnitedHealth’s higher P/E can be partly justified by its lower risk profile and consistent dividend yield, which stands at 1.5% as of July 2025, compared to Novo Nordisk’s more modest 0.9%. For risk-averse investors, UnitedHealth offers a safer bet, especially given its resilience during economic downturns, as evidenced by its performance in 2022 when revenues grew 13% despite market volatility, compared to a more pronounced 17% in 2024.

Conversely, Novo Nordisk’s valuation might reflect market concerns over patent cliffs or competitive pressures in the obesity drug space by the late 2020s. Yet, with current data showing sustained demand and limited near-term competition, the risk appears overstated at present.

Conclusion: Weighing the Balance

Both Novo Nordisk and UnitedHealth Group offer distinct propositions for investors in mid-2025. Novo Nordisk presents a compelling case for growth-focused portfolios, with a valuation that appears to lag behind its fundamentals. UnitedHealth Group, meanwhile, provides stability and a broader exposure to the healthcare ecosystem, albeit at a price that may already reflect much of its upside. The choice between the two hinges on an investor’s risk tolerance and time horizon, but the numbers suggest Novo Nordisk might hold the edge for those willing to bet on the explosive potential of targeted therapeutics over the next decade.

References

• 24/7 Wall St. (2025, July 21). Novo Nordisk A/S (NVO) Price Prediction and Forecast 2025-2030. Retrieved from https://247wallst.com/forecasts/2025/07/21/novo-nordisk-a-s-nvo-price-prediction-and-forecast-2025-2030/
• Bloomberg. (2025, July 23). Novo Nordisk A/S (NVO) Financial Metrics. Retrieved from https://www.bloomberg.com/quote/NVO:US
• Bloomberg. (2025, July 23). UnitedHealth Group (UNH) Financial Metrics. Retrieved from https://www.bloomberg.com/quote/UNH:US
• Google Finance. (n.d.). Novo Nordisk A/S. Retrieved July 2025, from https://www.google.com/finance/quote/NVO:NYSE?hl=en
• Investing.com. (n.d.). Novo Nordisk A/S (NVO) Stock Price, News, Quote & History. Retrieved July 2025, from https://www.investing.com/equities/novo-nordis
• MMatters22596 [@MMatters22596]. (2025, July). [Post on X]. Retrieved from https://x.com/MMatters22596/status/1931332186382258369
• MMatters22596 [@MMatters22596]. (2025, July). [Post on X]. Retrieved from https://x.com/MMatters22596/status/1932807298298065242
• MMatters22596 [@MMatters22596]. (2025, July). [Post on X]. Retrieved from https://x.com/MMatters22596/status/1936419626788765797
• MMatters22596 [@MMatters22596]. (2025, July). [Post on X]. Retrieved from https://x.com/MMatters22596/status/1938232789008015761
• MMatters22596 [@MMatters22596]. (2025, July). [Post on X]. Retrieved from https://x.com/MMatters22596/status/1939345768357187882
• Nasdaq. (n.d.). Should You Buy UnitedHealth Stock Instead of Novo Nordisk Stock? Retrieved July 2025, from https://www.nasdaq.com/articles/should-you-buy-unitedhealth-stock-instead-novo-nordisk-stock
• Novo Nordisk A/S. (2025, July). Q2 2025 Earnings Release. Retrieved from https://www.novonordisk.com/investors/financial-reports.html
• Seeking Alpha. (2025, July 22). Novo Nordisk’s Moat Is Deeper Than You Think. Retrieved from https://seekingalpha.com/article/4802957-novo-nordisks-moat-is-deeper-than-you-think
• The Fool. (2025, June 12). Should You Buy UnitedHealth Stock Instead of Novo Nordisk Stock?. Retrieved from https://www.fool.com/investing/2025/06/12/should-you-buy-unitedhealth-stock-instead-of-novo/
• The Fool. (2025, July 20). A Once-in-a-Lifetime Opportunity? This Blue Chip Healthcare Stock Is Down 20%. Retrieved from https://fool.com/investing/2025/07/20/a-once-in-a-lifetime-opportunity-this-blue-chip-he
• The Fool. (2025, July 22). 2 Beaten-Down Dividend Growth Stocks to Buy Now. Retrieved from https://www.fool.com/investing/2025/07/22/2-beaten-down-dividend-growth-stocks-to-buy-now/
• The Globe and Mail. (n.d.). 2 Beaten-Down Dividend Growth Stocks to Buy on the Dip. Retrieved July 2025, from https://theglobeandmail.com/investing/markets/stocks/NVO/pressreleases/33548800/2-beaten-down-dividend-growth-stocks-to-buy-on-the-dip
• UnitedHealth Group. (2025, July). Q2 2025 Earnings Release. Retrieved from https://www.unitedhealthgroup.com/investors/quarterly-earnings.html
• Yahoo Finance. (n.d.). Novo Nordisk A/S (NVO) Stock Price, News, Quote & History. Retrieved July 2025, from https://finance.yahoo.com/quote/NVO/